2013 Press Releases

Keyword Search
2017 | 2016 | 2015 | 2014 | 2013
Catabasis Initiates Phase 2 Trial of CAT-2003 in Patients with Severe Hypertriglyceridemia
Catabasis Closes $32.4 Million Series B Financing
Catabasis Names Ian Sanderson Chief Financial Officer
Catabasis to Present Phase 1 Data from Oral SMART Linker Conjugate CAT-2003 at Upcoming Conference
Catabasis Initiates Phase 2 Trial of CAT-2003 in Patients with Hypertriglyceridemia and Hypercholesterolemia
Catabasis’ CAT-2003 Demonstrates Significant Reduction of Fasting and Post-Prandial Triglycerides in Successful Phase 1 Trial
Catabasis Pharmaceuticals Announces Issuance of Patents for CAT-1000 and CAT-2000 Series
Cambridge-Based Catabasis Pharmaceuticals To Sponsor MDA Scientific Conference
Catabasis Initiates Phase 1 Trial of CAT-2003 for Treatment of Severe Hypertriglyceridemia
Catabasis Announces Positive Phase 1 Data for CAT-1004 Validating the SMART Linker Technology Platform
The documents contained in (or directly accessible from) this website include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements containing the words “believes”, “expects”, “anticipates”, “plans”, “estimates” and similar expressions. There are a number of important factors that could cause Catabasis’ actual results to differ materially from those indicated by such forward-looking statements, including factors identified in the company’s most recent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date such statement was first made.